ReviewDementia and neurocognitive disorders2017
Subjective Cognitive Decline and Alzheimer's Disease Spectrum Disorder.
Review in Dementia and neurocognitive disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- APOE in subjective cognitive decline: a systematic review and meta-analysis.Journal of neurology · 2026Pooled it
- Unraveling the Controversy: The Causal Link Between Osteoarthritis and Alzheimer's Disease.Brain and behavior · 2025Pooled it
- Evaluating measurement properties of subjective cognitive decline self-reported outcome measures: a systematic review.Systematic reviews · 2022Pooled it
- Single odor identification in subjective cognitive decline, mild cognitive impairment and Alzheimer's dementia.Wiener klinische Wochenschrift · 2026Article
- Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review.Journal of clinical medicine · 2026Review
- Cognitive assessment in heart failure: clinical value, timing, and practical tools.Heart failure reviews · 2026Review
- Article
- Hand Grip Strength Predicts Cognitive Decline in Subjective Cognitive Decline: 2-Year Follow-up Results.Journal of Korean medical science · 2026Article
- Early prediction of Alzheimer's disease using longitudinal electronic health records of US military veterans.Communications medicine · 2026Article
- Baseline facial emotion recognition is associated with clinical decline across the Alzheimer's disease spectrum: a multi-instrument longitudinal assessment study.Frontiers in aging neuroscience · 2026Article
- Use of Amyloid Positron-Emission Tomography to Diagnose Alzheimer's Disease in Clinical Practice in South Korea: Expert Recommendations.Journal of clinical neurology (Seoul, Korea) · 2025Review
- TNF-α Levels Are Increased in Patients with Subjective Cognitive Impairment and Are Negatively Correlated with β Amyloid-42.Antioxidants (Basel, Switzerland) · 2024Article
- Clinical Significance of Physical Frailty in Subjects With Subjective Cognitive Decline: A Prospective Study With Amyloid PET Data.Journal of clinical neurology (Seoul, Korea) · 2023Article
- Impacts of baseline biomarkers on cognitive trajectories in subjective cognitive decline: the CoSCo prospective cohort study.Alzheimer's research & therapy · 2023Observational
- Article
- Traceability and comparability through crosswalks with the NeuroMET Memory Metric.Scientific reports · 2023Article
- Differential associations of visual memory with hippocampal subfields in subjective cognitive decline and amnestic mild cognitive impairment.BMC geriatrics · 2022Article
- Specific depression dimensions are associated with a faster rate of cognitive decline in older adults.Alzheimer's & dementia (Amsterdam, Netherlands) · 2022Article
- Power Spectral Changes of Quantitative EEG in the Subjective Cognitive Decline: Comparison of Community Normal Control Groups.Neuropsychiatric disease and treatment · 2021Article
- Dual-task tests discriminate between dementia, mild cognitive impairment, subjective cognitive impairment, and healthy controls - a cross-sectional cohort study.BMC geriatrics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subjective cognitive decline (SCD) represents subjective complaints about cognitive decline in the absence of objective impairment in neuropsychological tests. Recently, growing evidence has suggested that SCD might be the first symptomatic stage of Alzheimer's disease (AD) spectrum disorders. However, SCD is a heterogeneous condition mixed with AD and non-AD related conditions. Hence, refinement of evidence from previous reports and standardization of the concept about SCD are needed to define appropriate target population with AD pathology. In this article, we review previous studies involving subjects with SCD, the new proposed research criteria, and characteristics of SCD in the aspect of preclinical AD. Biomarker status of SCD is also addressed. Future researches on SCD require a longitudinal follow-up with sufficient biomarker studies and proper outcome measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.